BigHat Biosciences Raises $75 Million to Advance AI-Designed Therapeutics

BigHat Biosciences, an AI-native biotechnology company, has announced it raised $75 million in its Series C financing. The round was co-led by DFJ Growth & Premji Invest and brings BigHat's total funding to date to $223 million.

The financing will support the growth of BigHat's leading platform for rapid data generation to power frontier intelligence for protein design, as well as advancement of the company's pipeline of AI-designed therapeutics.

BigHat has built an autonomous AI and experimental platform that generates proprietary biological data at scale. The company has already advanced its first program into the clinic, dosing the first patient in a Phase 1 trial evaluating lead program BHB810, a novel CDH17-directed antibody-drug conjugate for gastric cancer and other advanced gastrointestinal tumors.

BHB810 is one of the first AI-driven biologics to reach humans. BigHat has also nominated its second development candidate, BHB299, an avidity-driven T-cell engager designed to selectively target CEACAM6-expressing solid tumors, which is nearing completion of preclinical development.

The company has forged valuable collaborations with leading companies, including Amgen, Merck, Johnson & Johnson (J&J), AbbVie and Lilly. Since forming these collaborations, BigHat has announced successful completion of a strategic collaboration with J&J and three project collaborations with Merck.